A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $17 to $23
Travere Therapeutics Price Target Cut to $19.00/Share From $23.00 by Citigroup
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $18 to $23
Travere Therapeutics Remains Attractive Despite 'Disappointing' Halt on Pegtibatinase Trial, Wedbush Says
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Travere Slips After Pausing Late-stage Trial's Enrollments
B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Travere Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $18 From $23
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Travere Therapeutics Voluntarily Pauses Enrollment in Phase 3 Harmony Trial
12 Health Care Stocks Moving In Thursday's After-Market Session
Express News | Travere Therapeutics Inc - Currently Enrolled Patients to Continue Receiving Study Medication
Express News | Travere Therapeutics Inc - R&D Expenses Expected to Be Reduced by More Than $30 Million in 2025
Express News | Travere Therapeutics Inc - Enrollment in Phase 3 Harmony Study Expected to Restart in 2026
Express News | Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 Harmony Study of Pegtibatinase Related to Commercial Manufacturing Scale-up
JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $23
Travere Therapeutics Analyst Ratings
J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $23
J.P. Morgan analyst Anupam Rama maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and adjusts the target price from $20 to $23.According to TipRanks data, the analyst has a success rate of 4
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)